Table 1. Non-human primate studies with EBV gp350.
| Vaccine | Adjuvant | Study and results |
|---|---|---|
| Purified native gp350 | Lipsomes | Cotton top tamarins protected from EBV- induced lymphoma29 |
| Purified native gp350 | ISCOMs | Cotton top tamarins protected from EBV- induced lymphoma60 |
| Purified native gp350 | Muramyl dipeptide in squalene | Cotton top tarmarins protected from EBV- induced lymphoma61 |
| Adenovirus-gp350 | None | Cotton top tamarins protected from EBV- induced lymphoma30 |
| Vaccinia-gp350 WR strain | None | Cotton top tamarins protected from EBV- induced lymphoma31 |
| Vaccinia-gp350 Wyeth strain | None | Cotton top tamarins not protected from EBV- induced lymphoma31 |
| Vaccinia-gp350 | None | Common marmosets had decreased virus replication of EBV after challenge62 |
| Recombinant gp350 | Muramyl dipepide in squalene | Cotton top tamarins protected from EBV- induced lymphoma63 |
| Recombinant gp350 | Alum | Cotton top tamarins protected from EBV- induced lymphoma64 |
| Recombinant gp350 | Alum | Common marmosets had decreased virus replication of EBV after challenge65 |
Abbreviations: EBV, Epstein–Barr virus; ISCOMs, immunostimulating complexes WR strain, Western reserve strain.